Global Peptide–Drug Conjugates (PDCs) Market

Report ID : 1351 | Published : 2022-08-10 | Pages: | Format: PDF/EXCEL

Global Peptide–drug Conjugates (PDCs) Market size is expected to grow at a compound annual growth rate (CAGR) of 13.7% from 2022 to 2030. The emergence of Peptide–Drug Conjugates (PDCs) therapy for patients suffering from different cancers is believed to create several clinical opportunities during the forecast period. Peptide drug conjugates comprise three vital components: a homing peptide, a linker, and a cytotoxic payload that targets the tumour cell to release the cytotoxin. PDC targets tumour cells with a peptide chain of about ten amino acids, and its molecular weight is smaller than Antibody Drug Conjugates (ADCs), which can be rapidly enriched to tumour sites, while drug molecules in blood can be cleared quickly with a short half-life, helping to reduce toxic side effects caused by off-targeting. Due to the increasef popularity of ADCs, the pharmaceutical industry has been pushed to investigate additional drug conjugates, resulting in the development of a vast array of innovative Conjugated Drugs.

Therapeutic drugs are anticipated to be driven by the rising partnerships, mergers, and acquisitions of market players. The increasing number of pharmaceutical drug innovations is expected to fuel the growth of peptide–drug conjugates (PDCs) market in the near future. Also, in the coming days, there will be rapid approval of peptide drug conjugates in treating cancers due to the robust clinical pipeline of drugs. Major driving factors of peptide–drug conjugates (PDCs) market are the increasing need for therapeutic drugs, high prevalence of cancer diseases, rising number of clinical trials, and increasing investments by key players to develop promising therapies. Furthermore, advanced medical technologies, population growth, and the growing number of health-conscious people enhance the market growth.

However, the high-cost treatments, complex procedures, and lack of strict government laws limit the market growth. In addition, the pipeline product approval process may get responsible for the delayed product launch, and production as a lot of clinical trials are progressive stages. FDA has approved very few pipeline products regarding peptide drug conjugates in the last five years, which will impact the market's forecasting period.

The Peptide Drug conjugate Market is segmented by products and indications. Product segmentation consists of Lutetium Lu 177 dotatate, Melflufen, ANG1005, BT1718, CBX-12, and Other Pipeline Products. By Indication, it is divided into Relapsed/Refractory Multiple Myeloma, Neuroendocrine Tumors (NETs), Gastric Cancers, Acromegaly, Ophthalmology, and Other Cancer Indications. Both segments play a vital role in the worldwide peptide drug conjugate market. The peptide–drug conjugates (PDCs) market is divided into North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. North America, followed by Europe, holds the maximum market share due to the high prevalence of cancer, increased research and development expenditure, and fast adaption of advanced technologies. Due to factors such as growing per capita healthcare spending, well-established research facilities for the development of innovative PDCs, preclinical research, and increased research on advanced drug discoveries, the United States has the largest market share in the North American region

The Significant market players are Novartis AG, AstraZeneca, Bicycle Therapeutics, Cybrexa Therapeutics, Esperance Pharmaceuticals, Oncopeptides AB, Pepgen Corporation, Soricimed Biopharma, Theratechnologies, Pfizer Inc, Validus Pharmaceuticals LLC, Antisense Therapeutics, Midatech Pharma PLC, Ipsen Pharma, Chiasma, Inc., Peptron, Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc., Pharmaspur, Aspireo Pharmaceuticals, Ionis Pharmaceuticals Inc, Midatech Pharma Plc, and Other Prominent Players.

  • Novartis AG
  • AstraZeneca
  • Bicycle Therapeutics
  • Cybrexa Therapeutics
  • Esperance Pharmaceuticals
  • Oncopeptides AB
  • Pepgen Corporation
  • Soricimed Biopharma
  • Theratechnologies
  • Pfizer Inc
  • Validus Pharmaceuticals LLC
  • Antisense Therapeutics
  • Midatech Pharma PLC
  • Ipsen Pharma
  • Chiasma, Inc.
  • Peptron, Inc.
  • CRINETICS PHARMACEUTICALS
  • Dauntless Pharmaceuticals
  • Camurus AB
  • Teva Pharmaceuticals Inc.
  • Pharmaspur
  • Aspireo Pharmaceuticals
  • Ionis Pharmaceuticals Inc
  • Midatech Pharma Plc
  • Other Prominent Players

 Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Peptide-drug Conjugates Market Snapshot

Chapter 4. Global Peptide-drug Conjugates Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 2: By Products Estimates & Trend Analysis

5.1. By Products & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Products:

5.2.1. Lutetium Lu 177 dotatate

5.2.2. Melflufen

5.2.3. ANG1005

5.2.4. BT1718

5.2.5. CBX-12

5.2.6. Other Pipeline Products

Chapter 6. Market Segmentation 4: By Indications Estimates & Trend Analysis

6.1. By Indications & Market Share, 2020& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Indications:

6.2.1. Relapsed/Refractory Multiple Myeloma

6.2.2. Neuroendocrine Tumors (NETs)

6.2.3. Gastric Cancers

6.2.4. Acromegaly

6.2.5. Ophthalmology

6.2.6. Other Cancer Indication

Chapter 7. Peptide-drug Conjugates Market Segmentation 5: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Peptide-drug Conjugates Market revenue (US$ Million) estimates and forecasts By Products, 2019-2030

7.1.2. North America Peptide-drug Conjugates Market revenue (US$ Million) estimates and forecasts By Therapy, 2019-2030

7.1.3. North America Peptide-drug Conjugates Market revenue (US$ Million) estimates and forecasts by Indications, 2019-2030

7.1.4. North America Peptide-drug Conjugates Market revenue (US$ Million) estimates and forecasts by country, 2019-2030

7.2. Europe

7.2.1. Europe Peptide-drug Conjugates Market revenue (US$ Million) By Products, 2019-2030

7.2.2. Europe Peptide-drug Conjugates Market revenue (US$ Million) By Therapy, 2019-2030

7.2.3. Europe Peptide-drug Conjugates Market revenue (US$ Million) estimates and forecasts by Indications, 2019-2030

7.2.4. Europe Peptide-drug Conjugates Market revenue (US$ Million) by country, 2019-2030

7.3. Asia Pacific

7.3.1. Asia Pacific Peptide-drug Conjugates Market revenue (US$ Million) By Products, 2019-2030

7.3.2. Asia Pacific Peptide-drug Conjugates Market revenue (US$ Million) By Therapy, 2019-2030

7.3.3. Asia Pacific Peptide-drug Conjugates Market revenue (US$ Million) estimates and forecasts by Indications, 2019-2030

7.3.4. Asia Pacific Peptide-drug Conjugates Market revenue (US$ Million) by country, 2019-2030

7.4. Latin America

7.4.1. Latin America Peptide-drug Conjugates Market revenue (US$ Million) By Products, 2019-2030

7.4.2. Latin America Peptide-drug Conjugates Market revenue (US$ Million) By Therapy, 2019-2030

7.4.3. Latin America Peptide-drug Conjugates Market revenue (US$ Million) estimates and forecasts by Indications, 2019-2030

7.4.4. Latin America Peptide-drug Conjugates Market revenue (US$ Million) by country, 2019-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Peptide-drug Conjugates Market revenue (US$ Million) By Products, 2019-2030

7.5.2. Middle East & Africa Peptide-drug Conjugates Market revenue (US$ Million) By Therapy, 2019-2030

7.5.3. Middle East & Africa Peptide-drug Conjugates Market revenue (US$ Million) estimates and forecasts by Indications, 2019-2030

7.5.4. Middle East & Africa Peptide-drug Conjugates Market revenue (US$ Million) by country, 2019-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles 

8.2.1. Novartis AG

8.2.2. AstraZeneca

8.2.3. Bicycle Therapeutics

8.2.4. Cybrexa Therapeutics

8.2.5. Esperance Pharmaceuticals

8.2.6. Oncopeptides AB

8.2.7. Pepgen Corporation

8.2.8. AstraZeneca

8.2.9. Soricimed Biopharma

8.2.10. Theratechnologies

8.2.11. Pfizer Inc

8.2.12. Validus Pharmaceuticals LLC

8.2.13. Antisense Therapeutics

8.2.14. Midatech Pharma PLC

8.2.15. Ipsen Pharma

8.2.16. Chiasma, Inc.

8.2.17. Peptron, Inc.

8.2.18. CRINETICS PHARMACEUTICALS

8.2.19. Dauntless Pharmaceuticals

8.2.20. Camurus AB

8.2.21. Teva Pharmaceuticals Inc.

8.2.22. Pharmaspur

8.2.23. Aspireo Pharmaceuticals

8.2.24. Ionis Pharmaceuticals Inc

8.2.25. Midatech Pharma Plc

8.2.26. Other Prominent Players

Global Peptide–drug conjugates (PDCs) Market, by Product, 2022-2030 (Value US$ Mn)

  • Lutetium Lu 177 dotatate
  • Melflufen
  • ANG1005
  • BT1718
  • CBX-12
  • Other Pipeline Products

Global Peptide–drug conjugates (PDCs) Market, by Indication, 2022-2030 (Value US$ Mn)

  • Relapsed/Refractory Multiple Myeloma
  • Neuroendocrine Tumors (NETs)
  • Gastric Cancers
  • Acromegaly
  • Ophthalmology
  • Other Cancer Indication

Global Peptide–drug conjugates (PDCs) Market, by Region, 2022-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Peptide–drug conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Peptide–drug conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Peptide–drug conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Peptide–drug conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Peptide–drug conjugates (PDCs) Market, by Country, 2022-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa

Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Global Peptide–Drug Conjugates (PDCs) Market?

annual growth rate (CAGR) of 13.7% from 2022 to 2030

Our Clients